Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine

J Infect Dis. 2005 Oct 1;192(7):1260-4. doi: 10.1086/444424. Epub 2005 Aug 23.

Abstract

Single-dose nevirapine reduces intrapartum human immunodeficiency virus 1 type (HIV-1) transmission but may also select for nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance in breast milk (BM) and plasma. Among 32 Zimbabwean women, median 8-week postpartum plasma and BM HIV-1 RNA levels were 4.57 and 2.13 log(10) copies/mL, respectively. BM samples from women with laboratory-diagnosed mastitis (defined as elevated BM Na(+) levels) were 5.4-fold more likely to have HIV-1 RNA levels above the median. BM RT sequences were not obtained for 12 women with BM HIV-1 RNA levels below the lower limit of detection of the assay used. In 20 paired BM and plasma samples, 65% of BM and 50% of plasma RT sequences had NNRTI-resistance mutations, with divergent mutation patterns.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Drug Resistance, Viral*
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / transmission
  • HIV-1 / classification
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • HIV-1 / isolation & purification
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control
  • Milk, Human / microbiology*
  • Nevirapine / administration & dosage*
  • Pregnancy
  • RNA, Viral / blood
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Viral Load
  • Virus Shedding*
  • Zimbabwe

Substances

  • Anti-HIV Agents
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Nevirapine